← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	2,375	+108	+5%	$189B
2	2 Danaher DHR $158B	2,120	+89	+4%	$151B
3	3 Novartis NVS $279B	1,182	+94	+9%	$14.9B
4	4 Regeneron Pharmaceuticals REGN $80.1B	1,158	+78	+7%	$66.5B
5	5 Agilent Technologies A $49.1B	964	+66	+7%	$38.6B
6	6 Illumina ILMN $41B	943	+46	+5%	$28.6B
7	7 Charles River Laboratories CRL $14.4B	627	+45	+8%	$10.8B
8	8 Revvity RVTY $17B	614	+66	+12%	$14.8B
9	9 Alnylam Pharmaceuticals ALNY $30B	487	-10	-2%	$28.3B
10	10 DELISTED CATALENT, INC. CTLT	485	-21	-4%	$8.34B
11	11 Sarepta Therapeutics SRPT $1.78B	411	+35	+9%	$10.2B
12	12 CRISPR Therapeutics CRSP $4.86B	396	-39	-9%	$2.23B
13	13 Azenta AZTA $1.63B	350	+9	+3%	$4.23B
14	14 Ionis Pharmaceuticals IONS $7.1B	339	-11	-3%	$4.92B
15	15 ARK Genomic Revolution ETF ARKG $2.05B	321	+9	+3%	$523M
16	16 Ginkgo Bioworks DNA $776M	320	+42	+15%	$1.68B
17	17 Bruker BRKR $8.47B	302	+22	+8%	$7B
18	18 Intellia Therapeutics NTLA $1.6B	302	-19	-6%	$2.69B
19	19 Qiagen QGEN $9.41B	296	0	0%	$6.73B
20	20 Guardant Health GH $21.9B	290	-38	-12%	$2.53B
21	21 Arrowhead Research ARWR $8.25B	280	+3	+1%	$2.97B
22	NVTA 22 DELISTED Invitae Corporation NVTA	275	-9	-3%	$335M
23	23 10x Genomics TXG $9.52B	266	+33	+14%	$3.19B
24	24 Editas Medicine EDIT $349M	249	-16	-6%	$465M
25	25 Pacific Biosciences PACB $619M	235	+9	+4%	$1.83B